GenMont Biotech Inc (3164) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GenMont Biotech Inc (3164) has a cash flow conversion efficiency ratio of 0.011x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$15.46 Million ≈ $487.07K USD) by net assets (NT$1.41 Billion ≈ $44.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 3164 equity financing ratio to measure how much of total assets are equity-financed.
GenMont Biotech Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how GenMont Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is GenMont Biotech Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
GenMont Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenMont Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ashmore Asset Management Indonesia
JK:AMOR
|
0.001x |
|
Claranova SE
PA:CLA
|
-1.143x |
|
ALANDEQGRP FPO
AU:AEG
|
-1.327x |
|
Covalon Technologies Ltd.
V:COV
|
0.218x |
|
SOLUCIONES CUATROO.EO-04
F:5XW
|
N/A |
|
Yufo Electronics Co Ltd
TWO:6194
|
0.045x |
|
Krynica Vitamin SA
WAR:KVT
|
0.004x |
|
ALPINA HOLDINGS
F:B0M
|
N/A |
Annual Cash Flow Conversion Efficiency for GenMont Biotech Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of GenMont Biotech Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see 3164 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.45 Billion ≈ $45.67 Million |
NT$73.60 Million ≈ $2.32 Million |
0.051x | -39.40% |
| 2024-12-31 | NT$1.48 Billion ≈ $46.62 Million |
NT$123.95 Million ≈ $3.90 Million |
0.084x | +250.84% |
| 2023-12-31 | NT$1.45 Billion ≈ $45.66 Million |
NT$34.60 Million ≈ $1.09 Million |
0.024x | -74.09% |
| 2022-12-31 | NT$1.50 Billion ≈ $47.17 Million |
NT$137.95 Million ≈ $4.35 Million |
0.092x | +25.79% |
| 2021-12-31 | NT$1.52 Billion ≈ $48.03 Million |
NT$111.66 Million ≈ $3.52 Million |
0.073x | -8.23% |
| 2020-12-31 | NT$1.48 Billion ≈ $46.69 Million |
NT$118.27 Million ≈ $3.73 Million |
0.080x | +55.11% |
| 2019-12-31 | NT$1.45 Billion ≈ $45.62 Million |
NT$74.52 Million ≈ $2.35 Million |
0.051x | +43.51% |
| 2018-12-31 | NT$1.56 Billion ≈ $49.23 Million |
NT$56.03 Million ≈ $1.77 Million |
0.036x | -36.63% |
| 2017-12-31 | NT$1.37 Billion ≈ $43.19 Million |
NT$77.56 Million ≈ $2.44 Million |
0.057x | +59.70% |
| 2016-12-31 | NT$1.28 Billion ≈ $40.32 Million |
NT$45.34 Million ≈ $1.43 Million |
0.035x | +1161.02% |
| 2015-12-31 | NT$1.50 Billion ≈ $47.27 Million |
NT$-5.01 Million ≈ $-157.84K |
-0.003x | +91.40% |
| 2014-12-31 | NT$1.60 Billion ≈ $50.32 Million |
NT$-62.00 Million ≈ $-1.95 Million |
-0.039x | -132.38% |
| 2013-12-31 | NT$837.28 Million ≈ $26.38 Million |
NT$100.37 Million ≈ $3.16 Million |
0.120x | +538.11% |
| 2012-12-31 | NT$861.62 Million ≈ $27.15 Million |
NT$-23.58 Million ≈ $-742.77K |
-0.027x | -161.99% |
| 2011-12-31 | NT$904.75 Million ≈ $28.50 Million |
NT$39.94 Million ≈ $1.26 Million |
0.044x | -83.72% |
| 2010-12-31 | NT$737.87 Million ≈ $23.25 Million |
NT$200.03 Million ≈ $6.30 Million |
0.271x | +58.78% |
| 2009-12-31 | NT$635.68 Million ≈ $20.03 Million |
NT$108.53 Million ≈ $3.42 Million |
0.171x | +3.44% |
| 2008-12-31 | NT$609.60 Million ≈ $19.21 Million |
NT$100.62 Million ≈ $3.17 Million |
0.165x | +99.72% |
| 2007-12-31 | NT$524.64 Million ≈ $16.53 Million |
NT$43.36 Million ≈ $1.37 Million |
0.083x | +29.07% |
| 2006-12-31 | NT$461.75 Million ≈ $14.55 Million |
NT$29.56 Million ≈ $931.43K |
0.064x | +94.99% |
| 2005-12-31 | NT$290.14 Million ≈ $9.14 Million |
NT$9.53 Million ≈ $300.15K |
0.033x | -- |
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan … Read more